GAMMA Investing’s Phathom Pharmaceuticals PHAT Stock Holding History

GAMMA Investing’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.69K	Buy	505 +105	+26%	+$990	﹤0.01%	3770
2026 Q2	$4.34K	Sell	400 -38	-9%	-$434	﹤0.01%	3528
2026 Q1	$4.87K	Buy	438 +135	+45%	+$1.71K	﹤0.01%	3371
2025 Q4	$5.03K	Sell	303 -57	-16%	-$814	﹤0.01%	3267
2025 Q3	$4.24K	Buy	360 +336	+1,400%	+$3.47K	﹤0.01%	3241
2025 Q2	$230	Sell	24 -703	-97%	-$3.89K	﹤0.01%	3712
2025 Q1	$4.56K	Buy	727 +219	+43%	+$1.33K	﹤0.01%	3121
2024 Q4	$4.13K	Buy	508 +354	+230%	+$4.38K	﹤0.01%	2994
2024 Q3	$2.78K	Buy	154 +147	+2,100%	+$2.06K	﹤0.01%	2956
2024 Q2	$72	Sell	7 -16	-70%	-$165	﹤0.01%	3415
2024 Q1	$244	Buy	23 +16	+229%	+$136	﹤0.01%	3207
2023 Q4	$47	Buy	+7	New	+$60	﹤0.01%	3161

Other funds holding PHAT

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MWP

Meriwether Wealth & Planning Minden, Louisiana $222M AUM 15.77% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

EWP

Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return

GAMMA Investing's PHAT Position: Q3 2026 in Review

GAMMA Investing increased its Phathom Pharmaceuticals (PHAT) stake by 26% in Q3 2026, buying an estimated $990 and bringing the position to 505 shares worth $3.69K. The position accounts for ﹤0.01% of the portfolio, ranked #3770.

GAMMA Investing first reported a position in PHAT in Q4 2023 and has held it in 12 quarters since. The position peaked at $5.03K in Q4 2025. 9 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

GAMMA Investing held 505 shares of Phathom Pharmaceuticals worth $3.69K as of Q3 2026.
GAMMA Investing bought 105 Phathom Pharmaceuticals shares in Q3 2026, an estimated $990.
Phathom Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3770 holding.
GAMMA Investing first reported a position in Phathom Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
GAMMA Investing's Phathom Pharmaceuticals position peaked at $5.03K in Q4 2025.
9 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.